ENDOExpo Theaters

Join us at ENDOExpo Theater Booths #1345 and #2051 for informative presentations given by exhibitors and enjoy a free boxed lunch. (Seating is limited.)

Saturday, March 23, 2019

A New Auto-Injector in the Management of Hypogonadism
11:15 AM–12:15 PM | ENDOExpo, Booth 1345
Faculty:

  • Jesse N. Mills, MD, Department of Urology, UCLA, Los Angeles, CA
  • Rajib K. Bhattacharya, MD, University of Kansas School of Medicine, Kansas City, KS

This presentation will present a new choice in the management of testosterone deficiency.

The Endocrine Society thanks Antares Pharma, Inc. for supporting this program.

 

The Role of Sclerostin in the Regulation of Bone Mass and Strength
11:15 AM–12:15 PM | ENDOExpo, Booth 2051
Faculty: Mishaela R. Rubin, MD, Columbia University, New York, NY
This presentation will highlight how the glycoprotein sclerostin was discovered and the role that it plays in the regulation of bone mass. The effects of sclerostin on bone formation, resorption, mass, and strength, as well as the regulation of sclerostin expression will also be covered.

The Endocrine Society thanks Amgen for supporting this program.


Improved Outcomes Through Increased Patient Engagement with FreeStyle Libre 14 Day System
12:45 PM–1:45 PM | ENDOExpo, Booth 1345
Faculty: Ernest O. Asamoah, MD, Marion University Osteopathic School of Medicine, Indianapolis, IN
Join us to learn about the #1 CGM worldwide used by more than 1,300,000 people, FreeStyle Libre 14 day system. Dr. Ernest Asamoah, Clinical Assistant Professor of Medicine at Marion University Osteopathic School of Medicine, will share how he sees improved clinical outcomes and behavioral changes using the FreeStyle Libre 14 day system with his patients.

The Endocrine Society thanks Abbott Diabetes Care for supporting this program.


Advanced Clinical Conversations in Hypothyroidism
12:45 PM–1:45 PM | ENDOExpo, Booth 2051
Faculty: Todd W. Frieze, MD, FACP, FACE, ECNU, CCD, Hattiesburg Clinic, Biloxi, MS
The objectives of this program are to:

  • Recognize the complexity and widespread biological actions or thyroid hormones
  • Identify clinical challenges in the diagnosis and management of hypothyroidism
  • Explore complex cases of hypothyroidism in special populations and in patients with comorbid conditions.

The Endocrine Society thanks AbbVie, Inc. for supporting this program.


Sunday, March 24, 2019

Lower Together: LDL-C, Risk, Hassle, Cost
11:15 AM–12:15 PM | ENDOExpo, Booth 1345
Faculty: Honey East, MD, Premier Medical Group, Jackson, MS ExpoTheater
Join us for an educational presentation on the treatment of very high-risk patients described in the 2018 ACC/AHA Guidelines on the Management of Blood Cholesterol. Hear about Dr. Honey East’s experiences and the treatment options available for appropriate patients.

The Endocrine Society thanks Amgen for supporting this program.

 

Evolving Paradigms of Hypercortisolism
11:15 AM–12:15 PM | ENDOExpo, Booth 2051
Faculty: Ty B. Carroll, MD, Medical College of Wisconsin, Milwaukee, WI
Excessive cortisol activity causes multi-symptom dysfunction and may occur more commonly than previously thought. This program will focus on the range of symptoms and evolution in our understanding of hypercortisolism, focusing on its pathophysiology, the clinical consequences of excessive cortisol activity, screening recommendations, and relevant diagnostic testing.

The Endocrine Society thanks Corcept Therapeutics for supporting this program.


Reduce Cardiovascular Risk With VASCEPA® (icosapent ethyl): Evidence From REDUCE-IT™
12:45 PM–1:45 PM | ENDOExpo, Booth 1345
Faculty: Mary H. Honkanen, MD, Mobile Diagnostic Center, Mobile, AL
The unprecedented data from the VASCEPA® cardiovascular outcomes trial, REDUCE-IT™, and its potential impact on patient care will be evaluated in this presentation. Join the expert to discuss how to Reduce Cardiovascular Risk With VASCEPA® (icosapent ethyl): Evidence From REDUCE-IT™.

The Endocrine Society thanks Amarin Pharma for supporting this program.


Clinical Management of Adrenocortical Carcinoma
12:45 PM–1:45 PM | ENDOExpo, Booth 2051
Faculty:

  • Program Chair: Mouhammed Habra, MD, FACP, FACE, Department of Endocrine Neoplasia and Hormonal Disorders, MD Anderson Cancer Center, Houston, TX
  • Alice Levine, MD, Division of Endocrinology, Diabetes and Bone Disease at Mount Sinai, New York, NY
  • Camilo Jimenez, MD, Department of Endocrine Neoplasia and Hormonal Disorders, MD Anderson Cancer Center, Houston, TX

Adrenocortical Carcinoma (ACC) is a rare endocrine cancer with a median survival rate of 3-4 years. Mitotane is the main pharmacologic agent used alone or in combination with other chemotherapy for patients with inoperable, functional or nonfunctional ACC. This presentation will feature cases that provide attendees with recent evidence and recommendations about the clinical management of ACC.

The Endocrine Society thanks HRA Pharma for supporting this program.


Monday, March 25, 2019

An FDA-Approved Oral Solution Test to Diagnose Adult Growth Hormone Deficiency
12:45 PM–1:45 PM | ENDOExpo, Booth 1345
Faculty: Elena A. Christofides, MD, FACE, Endocrinology Associates, Inc., Columbus, OH
Learn about the only FDA-approved oral solution test indicated for the diagnosis of adult growth hormone deficiency. This presentation will review the registration trials for this innovative test and the steps for preparation and administration.

The Endocrine Society thanks Novo Nordisk Inc. for supporting this program.